BioSpace News Archive

Two innovative technologies from Dow (NYSE:DOW), the world’s leading materials science company, were recognized with 2020 BIG Innovation Awards presented by the Business Intelligence Group.

McKesson High Volume Solutions (HVS) and Coborn’s are pleased to announce the integration of ExpressRx Track with Coborn’s pharmacy operations.

Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorization for RUXIENCE™ (rituximab),1 a potential biosimilar to MabThera® (rituximab)

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the dosing of the first Alzheimer’s disease patient in the Phase 1b portion of the INTERCEPT clinical study of AL003.

Oncoceutics announced that the National Brain Tumor Society (NBTS) has committed to providing more than $200,000 in funding, with the potential for multiple years, to support a Phase II clinical trial of ONC201, the first imipridone dopamine receptor D2 antagonist (DRD2), in a molecular subset of high grade gliomas.

A positive opinion for the approval of the company’s single-dose oral cholera vaccine, Vaxchora ® (Cholera Vaccine, Live, Oral).

Ambra Health, makers of the leading cloud-based, medical image management suite, today announced its recognition as the 2020 KLAS Category Leader for Image Exchange.

PELITAS (“the Company”), a leading provider of healthcare Patient Access technology solutions, announced today that it has been recognized as 2020 Best in KLAS® for the Patient Access technology category.

Arcadia Analytics’ value-based care insights cited as key factor in earning top marks from surveyed customers [31-January-2020] BURLINGTON, Mass. , Jan. 31, 2020 /PRNewswire/ -- Arcadia ( arcadia.io ), a widely-recognized leader in population health management, today announced that the company was awarded the 2020 Best in KLAS designation for Value-Based Care Managed

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that researchers have successfully applied its ultra-sensitive Simoa technology to generate data on the value of blood biomarkers as research tools to study pathophysiological mechanisms of concussion and as potential clinical tools and objective indicators for sports-related concussions (SRCs) and mild traumatic brain injuries (mTBIs).